Since Src kinases collaborate with focal adhesion kinase (FAK) to signal towards cell survival and proliferation, we hypothesized that FAK inhibitors (FAKi), which continue to be clinically investigated, might also show utility against Rac1-driven drug-resistant melanoma cells. This evidence concerns the gene PTK2 and melanoma.